Welcome to our dedicated page for Novocure news (Ticker: NVCR), a resource for investors and traders seeking the latest updates and insights on Novocure stock.
NovoCure Limited develops and commercializes Tumor Treating Fields therapy for solid tumors through wearable medical devices including Optune Gio, Optune Lua and Optune Pax. News about NVCR centers on product approvals, reimbursement decisions, launch activity and the use of TTFields in glioblastoma, pancreatic cancer, non-small cell lung cancer and pleural mesothelioma.
Company updates also cover clinical programs such as PANOVA, LUNAR and KEYNOTE studies, quarterly financial results, research and clinical-study spending, and commercialization across the United States, Europe, Japan and other markets where the company has approved products.
Novocure (NASDAQ: NVCR) will report its second quarter 2026 financial results on July 23, 2026, before U.S. markets open.
Management will host a conference call and webcast at 8:00 a.m. EDT, with slides and a corporate presentation available via the company’s investor relations website.
Novocure (NASDAQ: NVCR) received a CE Mark for Optune Pax for adult patients with locally advanced pancreatic cancer of exocrine origin, used with gemcitabine and nab-paclitaxel.
The Phase 3 PANOVA-3 trial showed statistically significant gains in median overall survival, one-year survival, time to pain progression and several quality-of-life measures, with mostly mild-to-moderate device-related skin adverse events. Novocure plans to launch Optune Pax in Germany soon.
Novocure (NASDAQ: NVCR) reported topline Phase 3 TRIDENT data in newly diagnosed glioblastoma. Starting Tumor Treating Fields (TTFields) at chemoradiation did not significantly improve overall survival versus starting in maintenance (17.7 vs 17.5 months; HR 0.953; p=0.519).
Both arms showed durable 3‑year survival and no new safety signals; early TTFields initiation was feasible. TRIDENT enrolled 981 patients, with balanced baseline characteristics. Results will be presented at the ASTRO 2026 Annual Meeting.
Novocure (NASDAQ: NVCR) reported Q1 2026 results for the quarter ended March 31, 2026: net revenue $174.1M (+12% YoY), gross margin 78%, and net loss $71.1M (EPS -$0.62). Active patients totaled 4,791 globally. Optune Pax received U.S. FDA approval and recorded 169 prescriptions and 83 active U.S. patients in Q1. Novocure updated 2026 guidance to $690M–$710M revenue and Adjusted EBITDA of $(15)M–$0M. Cash and short-term investments were $432.0M. Key upcoming milestones include TRIDENT topline (Q2 2026) and FDA decision on brain metastases (Q4 2026).
Novocure (NASDAQ: NVCR) will report first quarter 2026 financial results on April 30, 2026 before U.S. markets open. Management will host a conference call and webcast on April 30 at 8:00 a.m. EDT to discuss results for the quarter ended March 31, 2026.
Slides and the corporate presentation will be available via the company’s Investor Relations website and accessible for at least 14 days after the call. Novocure said it uses its investor relations website to disclose material information and comply with Regulation FD.
Novocure (NASDAQ: NVCR) reported positive topline results from the Phase 2 PANOVA-4 trial of Tumor Treating Fields (TTFields) used with atezolizumab plus gemcitabine and nab-paclitaxel as first-line therapy for metastatic pancreatic ductal adenocarcinoma.
PANOVA-4 met its primary endpoint: DCR 74.4% (N=78) vs a 48% historical control (difference 26.4%, one-sided p < 0.001). Secondary results: ORR 34.6% (95% CI 24.2%–46.2%) and median OS 9.7 months (95% CI 7.9–12.7). TTFields were well tolerated; additional data will be presented at a future scientific forum.
Novocure (NASDAQ: NVCR) announced that Japan's Ministry of Health, Labour and Welfare approved reimbursement for Optune Lua under the country’s National Health Insurance on March 2, 2026.
Optune Lua is indicated in Japan for adults with unresectable advanced/recurrent non-small cell lung cancer (NSCLC) who progressed after platinum-based chemotherapy, for concurrent use with PD-1/PD-L1 inhibitors. Eligible patients can access therapy at qualified health centers.
Novocure (NASDAQ: NVCR) said management will participate in the Leerink Global Healthcare Conference on March 10, 2026. CEO Frank Leonard and CFO Christoph Brackmann will hold a fireside chat at 11:20 a.m. EST and meet one-on-one with investors.
A live audio webcast will be available on the company’s Investor Relations site and replayable for at least 14 days.
Novocure (NASDAQ: NVCR) reported full‑year 2025 net revenues of $655.4 million (up 8% YoY) and Q4 net revenues of $174.4 million (up 8% YoY). The U.S. FDA approved Optune Pax for locally advanced pancreatic cancer and commercial launch is underway. Q4 net loss was $24.5 million, adjusted EBITDA was $(16.4) million, and cash, cash equivalents and short‑term investments were $447.7 million. 2026 guidance: $675M–$705M revenue and adjusted EBITDA $(20)M–$0M. Active patients on TTFields therapy totaled 4,620 at year‑end.
Novocure (NASDAQ: NVCR) announced that British Columbia will cover Tumor Treating Fields (TTFields) therapy for eligible adults with newly diagnosed glioblastoma, the first Canadian province to do so after Canada's drug agency recommendation.
TTFields was approved by Health Canada in 2022, is reimbursed in multiple countries, and has treated over 40,000 patients worldwide.